Radiology, Vol 167, 71-75, Copyright © 1988 by Radiological Society of North America
Breast cancer imaging with In-111 human IgM monoclonal antibodies: preliminary studies
KP Ryan, RO Dillman, SJ DeNardo, GL DeNardo, J Beauregard, PL Hagan, DG Amox, ML Clutter, KG Burnett and CM Rulot
Division of Hematology/Oncology, Veterans Administration Medical Center, San Diego, CA 92161.
Detection of specific tumor sites was studied with scintigraphy and
radiolabeled human IgM monoclonal antibodies (MoAbs). Ten patients with
metastatic breast cancer received an infusion of one of three indium-
111-labeled anti-breast carcinoma MoAbs. The time of infusion ranged from
30 minutes to 2 hours. Three patients received YBB-190 at total doses of 2,
4.25, or 11 mg, four patients received YBM-209 at total doses of 1 mg (n =
1) or 20 mg (n = 3), and three patients each received 22 mg of YBY-088.
Imaging was performed immediately after infusion and at 4, 24, 48, 72, 120,
and 144 hours. Many presumed sites of metastatic disease were imaged in
three of the four patients who received 20 mg of YBM-209 and in two of the
three patients who received YBY-088. Tumor was not detected in any of the
patients who received YBB- 190, in the patient who received a 1-mg dose of
YBM-209, or in the patient who received YBY-088 and in whom a biopsy of
tumor tissue failed to demonstrate target antigen. The authors conclude
that In-111- labeled human IgM MoAbs can target human breast cancer, but
antigen expression and antibody dose determine successful
immunoscintigraphy.
